Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Clever Marketing Needed To Position J&J's New Psoriasis Drug Ahead Of Cheaper Options

Executive Summary

Despite being able to show superiority over market leader AbbVie's Humira (adalimumab), Johnson & Johnson will need to invest heavily in order to drive uptake for guselkumab if the drug is successfully approved next year for the treatment of psoriasis.

Advertisement

Related Content

J&J Forges Ahead In Immunology Despite Competitive Dynamics
Keeping Track: FDA Approves First Rx DHEA, Receives Applications For Midostaurin, Gesulkumab, Biosimilar Avastin
ACR 2016 Roundup: Remicade Copy Not So Similar; Mixed Sirukumab Results; Corbus’s Resunab Surge
Sun Underlines 'Competitive Profile' Of Psoriasis Asset In Crowded Market
Novartis' Cosentyx Boosted By High Psoriasis Skin Clearance Over 4 Years

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC097397

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel